Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page




    The wide spectrum of neuropsychiatric complications in Covid-19 MESHD patients within a multidisciplinary hospital context

    Authors: Cecile Delorme; Marion Houot; Charlotte Rosso; Stephanie Carvalho; Thomas Nedelec; Redwan Maatoug; Victor Pitron; Salimata Gassama; Sara Sambin; Stephanie Bombois; Bastien Herlin; Gaelle Ouvrard; Gaelle Bruneteau; Adele Hesters; Ana Zenovia Gales; Bruno Millet; Foudil Lamari; Stephane Lehericy; Vincent Navarro; Benjamin Rohaut; Sophie Demeret; Thierry Maisonobe; Marion Yger; Bertrand Degos; Louise-Laure Mariani; Christophe Bouche; Nathalie Dzierzynski; Bruno Oquendo; Flora Ketz; An-Hung Nguyen; Aurelie Kas; Jean-Yves Delattre; Jean-Christophe Corvol

    doi:10.1101/2020.10.21.20216747 Date: 2020-10-23 Source: medRxiv

    Objective: To describe the spectrum of neurological and psychiatric complications MESHD in patients with Covid-19 MESHD seen in a multidisciplinary center over six months. Methods: We conducted a retrospective, observational study on all patients showing neurological or psychiatric MESHD symptoms in the context of Covid-19 MESHD seen in the Department of Neurology and Psychiatry of the APHP-Sorbonne University. We collected demographic data, medical and treatment history, comorbidities, symptoms, date of onset, and severity of Covid-19 MESHD infection, neurological and psychiatric symptoms MESHD, neurological and psychiatric MESHD examination data and, when available, results from cerebrospinal fluid (CSF) analysis, brain magnetic resonance (MRI) imaging, 18-fluorodesoxyglucose-position emission computed tomography (FDG-PET/CT)), electroencephalography (EEG) and electroneuromyography (ENMG). Results: 245 patients were included in the analysis. One-hundred fourteen patients (47%) were admitted to the intensive care unit (ICU) and 10 (4%) died. The most frequently reported neuropsychiatric symptoms were motor deficit (41%), cognitive disturbance MESHD (35%), impaired consciousness MESHD (26%), psychiatric disturbance MESHD (24%), headache MESHD (20%) and behavioral disturbance MESHD (18%). The most frequent syndromes diagnosed were encephalopathy MESHD (43%), critical illness polyneuropathy MESHD and myopathy MESHD (26%), isolated psychiatric disturbance MESHD (18%), and cerebrovascular disorders MESHD (16%). No patients showed evidence of SARS-CoV-2 in their CSF. Encephalopathy MESHD was associated with greater age and higher risk of death MESHD. Critical illness neuromyopathy MESHD was associated with an extended stay in the ICU. Conclusions: The majority of the neuropsychiatric complications recorded could be imputed to critical illness, intensive care and systemic inflammation MESHD, which contrasts with the paucity of more direct SARS-CoV-2-related complications or post- infection disorders MESHD.

    Critical Illness Polyneuropathy and Myopathy in COVID-19 MESHD Patients: A Prospective Observational Intensive Care Unit Cross-Sectional Cohort Study

    Authors: Robert Frithiof; Elham Rostami; Eva Kumlien; Johan Virhammar; David Fällmar; Michael Hultström; Miklós Lipcsey; Nicholas Ashton; Kaj Blennow; Henrik Zetterberg; Anna Rostedt Punga

    doi:10.21203/rs.3.rs-78038/v1 Date: 2020-09-15 Source: ResearchSquare

    Background: Several reports on neurological complications associated with SARS-CoV-2 infection MESHD have been published. However, systematic description on intensive care unit acquired weakness MESHD (ICUAW) are still missing. Methods: The objective was to determine the incidence and characteristics of critical illness polyneuropathy MESHD ( CIN MESHD CIN HGNC) and myopathy MESHD ( CIM HGNC) in patients with severe COVID-19 MESHD. We also aimed to describe the electrophysiological features and their relation to plasma biomarkers for neuronal injury MESHD. This was a prospective observational intensive care unit cohort study. All adult patients admitted to the general intensive care unit (ICU) at Uppsala University Hospital, Uppsala, Sweden, between March 13 and June 8, 2020 were screened for inclusion. Patients with PCR confirmed COVID-19 MESHD were included. All patients were admitted to intensive care treatment due to severe COVID-19 MESHD, including intravenous anaesthesia, opioid anaelgesia MESHD, neuromuscular blockade and mechanical ventilation. Associations of clinical, electrophysiological (sensory and motor conduction studies and electromyography) and biomarker data [neurofilament light chain ( NfL HGNC), glial fibrillary acidic protein ( GFAp HGNC) and tau] were studied between COVID-19 MESHD patients who developed CIN MESHD CIN HGNC/ CIM HGNC and those who did not. Results: 111 COVID-19 MESHD patients were included, 11 (11 males, mean age: 64 years) developed CIN HGNC CIN MESHD/ CIM HGNC whereas 100 (74 males, mean age: 61 years) did not (non- CIN HGNC CIN MESHD/ CIM HGNC). The CIN MESHD CIN HGNC/ CIM HGNC incidence was higher in COVID-19 MESHD patients compared to a general ICU-population treated during 2019 (9.9% vs 3.4%). In particular CIN MESHD CIN HGNC was more frequent in the COVID-19 MESHD ICU cohort (50%) compared with the non- COVID-19 MESHD ICU cohort (0%, p=0.008). NfL HGNC and GFAp HGNC levels were higher in the CIN MESHD CIN HGNC/ CIM HGNC group both at the early (<9 days) and late time points (>11 days) compared with the non- CIN MESHD CIN HGNC/ CIM HGNC group (both p=0.001) and correlated with nerve amplitudes. Conclusions: CIN MESHD CIN HGNC/ CIM HGNC, in particular CIN HGNC CIN MESHD, were more prevalent among COVID-19 MESHD patients than an ICU treated control cohort and should be considered in the differential diagnostic workup and the further rehabilitation of COVID-19 MESHD patients.  COVID-19 MESHD patients who later developed ICUAW had significantly higher NfL HGNC and GFAp HGNC in the early phase of ICU care, which suggests their potential as predictive biomarkers. Trial registration: The study protocol was registered (ClinicalTrialsID:NCT04316884). Mechanisms for Organ Dysfunction in Covid-19 MESHD (UMOD COVID19 MESHD) March 18, 2020.

    Guillain Barr e syndrome in COVID-19 MESHD:A scoping review

    Authors: Imran Ahmad; Farooq Azam Rathore

    doi:10.1101/2020.06.13.20130062 Date: 2020-06-16 Source: medRxiv

    Introduction The novel coronavirus ( COVID19 MESHD) can result in several neurological complications. Guillain-Barre Syndrome MESHD ( GBS MESHD) is one of them and has been reported from different parts of the world in this pandemic. It is an acute post-infectious polyneuropathy MESHD. The review aims to summarize the demographic features, clinical presentation, diagnostics workup, and management strategies of COVID-19 MESHD associated GBS MESHD reported in the literature. Material and method We searched Medline, PubMed Central, SCOPUS, and Google Scholar using pre-defined keywords, with no time limits and in the English language only. We aimed to include all kinds of manuscripts. The last search was done on 18th May 2020. Demographics, clinical features, diagnostic workup, management, and outcomes were documented in the datasheet. Results We identified 24 cases of COVID-19 MESHD associated GBS MESHD. Most of the cases were reported from Italy followed by the USA. The majority were males (18 /24) The age ranged from 23 -84 years. The clinical presentation was typical sensory-motor GBS MESHD in most. Nine patients had facial palsy of which five had bilateral involvement. Two patients had bilateral abducent nerve palsy MESHD while two presented as paraparetic GBS MESHD variant with autonomic dysfunction. Electrodiagnostics was performed in 17 patients only and 12 had typical features of acute inflammatory demyelinating polyneuropathy MESHD. Intravenous immunoglobulins were the preferred mode of treatment in most of the patient. There was one death MESHD, and most were discharged to rehabilitation or home. Conclusion GBS MESHD is a frequent neurological complication associated with COVID-19 MESHD. There is no clear causative relationship between GBS MESHD, and COVID-19 MESHD at present, and more data are needed to establish the casualty. However, most cases have a post-infectious onset with male preponderance. Most of the cases have a typical presentation but some may present in an atypical way. Prognosis is generally good.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.